<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648764</url>
  </required_header>
  <id_info>
    <org_study_id>11967</org_study_id>
    <secondary_id>2008-000807-28</secondary_id>
    <secondary_id>I1C-MC-JLBE</secondary_id>
    <nct_id>NCT01648764</nct_id>
  </id_info>
  <brief_title>A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread</brief_title>
  <official_title>Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two different dosing regimens of LY2334737 in
      participants with cancer that is advanced and/or has spread to other parts of the body.
      Information about side effects will be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a Dose Escalation Phase (Arms A and B) followed by a Dose
      Confirmation Phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose for phase 2 studies</measure>
    <time_frame>Baseline through study completion (approximately 49 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Baseline through Cycle 2, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Baseline through Cycle 2, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Baseline to measured disease progression (approximately 49 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline to measured disease progression or death (approximately 49 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with changes in QT interval (&gt;30 milliseconds) from baseline</measure>
    <time_frame>Days 1, 2, 21 and 22 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with changes in R-R interval from baseline</measure>
    <time_frame>Days 1, 2, 21, and 22 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Minimum plasma concentration (Cmin)</measure>
    <time_frame>Baseline through Cycle 2, Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Solid Tumor</condition>
  <condition>Metastatic Tumor</condition>
  <arm_group>
    <arm_group_label>LY2334737 - Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2334737 administered orally at escalating doses (40 mg - 200 mg) every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2334737 - Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2334737</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2334737 - Arm A</arm_group_label>
    <arm_group_label>LY2334737 - Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no
             treatment of higher priority exists

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Estimated life expectancy of more than 12 weeks

          -  Have discontinued all previous therapies for cancer for at least 30 days (6 weeks for
             mitomycin-C or nitrosoureas) and recovered from acute effects of therapy

          -  Have discontinued radiotherapy more than one week before enrolling in the study and
             have recovered from the acute affects of therapy

          -  Have adequate organ function

          -  Follow your doctor's directions and live close enough to the study site so you can
             continue to go to the clinic for follow-up

          -  Are willing and able to swallow capsules and follow study procedures

          -  Have given written informed consent prior to any study-specific procedures

          -  Males and females with reproductive potential should use medically approved
             contraceptive precautions during the study and for 6 months following the last dose of
             study drug

          -  Females with child-bearing potential must have had a negative urine or serum pregnancy
             test 7 days prior to the first dose of study drug

        Exclusion Criteria:

          -  Have gastrointestinal diseases or prior surgery that may interfere with the absorption
             of medication taken by mouth

          -  Females who are pregnant or lactating

          -  Symptomatic central nervous system malignancy or metastasis

          -  Known positive test results in human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBSAg), or hepatitis C antibodies (HCAb)

          -  Liver cirrhoses or chronic hepatitis

          -  Acute or chronic leukemia

          -  Are currently receiving treatment with valproic acid (VPA) and it's derivatives, or if
             you have a history of intolerance to VPA

          -  Known hypersensitivity to gemcitabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

